Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-RB: Episcleral Topotecan in Retinoblastoma
NCT04156347Phase 1Unknown
- Sponsor
- Targeted Therapy Technologies
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan in retinoblastoma (Rb), sponsored by Targeted Therapy Technologies. Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of Episcleral Topotecan at 9 Weeks. Status: unknown.
02
Drugs
topotecan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT04156347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156347.